SCHEMBL6801398

SCHEMBL6801398

Cc1ccc(-n2c(=O)n(O)c(=O)c3cc(F)c(N4CCCC4)nc32)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.37
FEN1 P39748 2/20 0.36
ERCC1 P07992 1/20 0.36
DNASE1 P24855 1/20 0.36
ERCC4 Q92889 1/20 0.36
MAPT P10636 4/20 0.35
TP53 P04637 2/20 0.35
POLB P06746 1/20 0.35
HTT P42858 2/20 0.35
TSHR P16473 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
KDM4E B2RXH2 3/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
LMNA P02545 2/20 0.34
CYP2C9 P11712 1/20 0.34
ATP6V1B2 P21281 1/20 0.34
TBXA2R P21731 1/20 0.34
EDNRA P25101 1/20 0.34
TARBP2 Q15633 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6800863 0.91 FEN1 (0.38) ALDH1A1FEN1ERCC1DNASE1ERCC4
SCHEMBL6796967 0.89 TRPV4 (0.41) ALDH1A1FEN1MAPTTP53POLB
SCHEMBL6800342 0.87 TRPV4 (0.40) FEN1ERCC1DNASE1ERCC4LMNA
SCHEMBL6801451 0.82 LMNA (0.39) ALDH1A1FEN1MAPTTP53POLB
SCHEMBL6801862 0.81 ALDH1A1 (0.39) ALDH1A1MAPTTP53POLBHTT
SCHEMBL6795621 0.80 KMT2A (0.42) ALDH1A1MAPTPOLBHTTSMN1; SMN2
SCHEMBL6801438 0.77 LMNA (0.43) ALDH1A1MAPTTSHRMEN1KMT2A
SCHEMBL6800507 0.76 KMT2A (0.51) ALDH1A1FEN1MAPTPOLBHTT
SCHEMBL6803855 0.75 EEF2K (0.37) FEN1ERCC1DNASE1ERCC4KMT2A
SCHEMBL6799791 0.73 ERCC5 (0.46) ALDH1A1FEN1ERCC1ERCC4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6825199-B2 7-Substituted quinazolin-2,4-diones useful as antibacterial agents WARNER-LAMBERT COMPANY 2004-11-30 US claimed
EP-1028950-B1 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS WARNER LAMBERT CO (US) 2003-05-02 EP claimed
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents DOMAGALA JOHN MICHAEL (US) 2002-08-22 US claimed
US-6825199-B2 7-Substituted quinazolin-2,4-diones useful as antibacterial agents WARNER-LAMBERT COMPANY 2004-11-30 US disclosed
EP-1028950-B1 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS WARNER LAMBERT CO (US) 2003-05-02 EP disclosed
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents DOMAGALA JOHN MICHAEL (US) 2002-08-22 US disclosed
US-6331538-B1 TREATMENT OF BACTERIAL INFECTION WARNER-LAMBERT COMPANY 2001-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents NQO2, TOP1, TOP2A ALDH1A1 3064/4885FEN1 2658/4885ERCC1 2318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.